

Substitute for Form PTO-1390		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 003301-231	
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>				U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>10/537538</b> Unassigned	
INTERNATIONAL APPLICATION NO. PCT/SE2003/001941		INTERNATIONAL FILING DATE 12 December 2003		PRIORITY DATE CLAIMED 16 December 2002, 16 December 2002	
TITLE OF INVENTION  TETRACYCLIC IMMUNOMODULATORY COMPOUNDS					
APPLICANT(S) FOR DO/EO/US IAN RICHARD MATTHEWS, PHILIP HUXLEY, FILIPPO MAGARACI, CHRIS JAMES BRENNAN, MUHAMMED KAMAL UDDIN, LARS OLOF GÖRAN PETTERSSON, and DORTHE DA GRAÇA THRIGE					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"><li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission to items concerning a filing under 35 U.S.C. 371.</li><li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li><li>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (22) indicated below.</li><li>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</li><li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))<ol style="list-style-type: none"><li>a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li><li>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</li><li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li></ol></li><li>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))<ol style="list-style-type: none"><li>a. <input type="checkbox"/> is attached hereto.</li><li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li></ol></li><li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))<ol style="list-style-type: none"><li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li><li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li><li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li><li>d. <input type="checkbox"/> have not been made and will not be made.</li></ol></li><li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li><li>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (Signed Declaration to follow).</li><li>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li></ol>					
Items 11 to 21 below concern document(s) or information included:					
<ol style="list-style-type: none"><li>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li><li>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li><li>13. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment.</li><li>14. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li><li>15. <input type="checkbox"/> A substitute specification.</li><li>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</li><li>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 C.F.R. 1.821 - 1.825.</li><li>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</li><li>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</li><li>20. <input checked="" type="checkbox"/> Other items or information: <u>A certified copy of Swedish Patent Application No. 0203722-4, filed 16 December 2002 was submitted during the international phase of the examination. Thus, the claim for priority has been perfected.</u></li></ol>					

U.S. APPLICATION NO. <u>10/537538</u> <small>(If known, see 37 CFR 1.55)</small>	INTERNATIONAL APPLICATION NO. PCT/SE2003/001941	ATTORNEY'S DOCKET NUMBER 003301-231
---	--	--

21. <input checked="" type="checkbox"/> Applicant(s) requests that the published application include the following assignment information: <u>ACTIVE BIOTECH AB, Lund, Sweden</u>         22. <input checked="" type="checkbox"/> The following fees are submitted:	<b>CALCULATIONS PTO USE ONLY</b>
--	----------------------------------

Basic Filing Fee (1631)	\$ 300.00																
Surcharge of <b>\$130.00 (1617)</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).																	
<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:25%;">CLAIMS</th> <th style="width:15%;">NUMBER FILED</th> <th style="width:15%;">NUMBER EXTRA</th> <th style="width:15%;">RATE</th> <th style="width:30%;">\$</th> </tr> <tr> <td>Total Claims</td> <td style="text-align: center;">20</td> <td style="text-align: center;">-20 =</td> <td style="text-align: center;">0</td> <td style="text-align: right;">X \$50.00 (1615)</td> </tr> <tr> <td>Independent Claims</td> <td style="text-align: center;">1</td> <td style="text-align: center;">-3 =</td> <td style="text-align: center;">0</td> <td style="text-align: right;">X \$200.00 (1614)</td> </tr> </table>	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	Total Claims	20	-20 =	0	X \$50.00 (1615)	Independent Claims	1	-3 =	0	X \$200.00 (1614)		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$													
Total Claims	20	-20 =	0	X \$50.00 (1615)													
Independent Claims	1	-3 =	0	X \$200.00 (1614)													
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$360.00 (1616)															
Examination Fee		+ \$200.00 (1633)	\$ 200.00														
Search Fee		+ \$500.00 (1632)	\$ 500.00														
App. Size Fee (add \$250.00 for each add'l 50 sheets exceeding 100 sheets)																	
TOTAL OF ABOVE CALCULATIONS			\$ 1,000.00														
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.	+		\$ 0.00														
	SUBTOTAL =		\$ 1,000.00														
Processing fee of <b>\$130.00 (1618)</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			\$ 0.00														
TOTAL NATIONAL FEE =			\$ 1,000.00														
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00 (8021)</b> per property +																	
TOTAL FEES ENCLOSED =			\$ 1,000.00														
		Amount to be refunded:															
		charged:															

a. ☒ A check in the amount of \$ 1,000.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. 02-4800 in the amount of \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4800. A duplicate copy of this sheet is enclosed.


d. ☐ Charge \_\_\_\_\_ to credit card. Form PTO-2038 is attached.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Burns, Doane, Swecker & Mathis, L.L.P.  
 P.O. Box 1404  
 Alexandria, Virginia 22313-1404  
 (703) 836-6620

  
 SIGNATURE  
 \_\_\_\_\_  
 Benton S. Duffett, Jr.  
 NAME  
 \_\_\_\_\_  
 22,030      June 3, 2005  
 REGISTRATION NO.      DATE